A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

BACKGROUND: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bernstein, S. H., Epner, E., Unger, J. M., LeBlanc, M., Cebula, E., Burack, R., Rimsza, L., Miller, T. P., Fisher, R. I.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660082/
https://ncbi.nlm.nih.gov/pubmed/23504948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt070
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados